Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.athoracsur.2019.11.004 | DOI Listing |
J Cardiothorac Vasc Anesth
May 2021
Miller School of Medicine, University of Miami, Miami, FL.
US Food and Drug Administration approval of the edge-to-edge clip repair device (MitraClip; Abbott Laboratories, Abbott Park, IL) in 2013 led to wide adoption of the device for treatment of severe primary mitral regurgitation in patients unsuitable for surgery. Demonstration of favorable outcomes in the setting of secondary mitral regurgitation by the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial in 2019 provided an additional impetus to the transcatheter mitral interventional program. The role of the cardiac anesthesia service also is expanding to echocardiography services for these patients outside of the procedure room.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
April 2020
American Association for Thoracic Surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!